Isto Biologics, a Thompson Street Capital-backed bone regeneration and cellular therapy company, is exploring a sale, according to three sources familiar with the matter. DC Advisory has been hired to oversee the sale effort of the Hopkinton, Massachusetts-based company, the sources said. The process has not yet launched, two sources said, with one of them adding that teasers are set to go out imminently. Isto is being marketed off EBITDA of about USD 50m, two sources said, with one of them noting that the EBITDA figure is adjusted to the end of 2025. The company is aiming for an EBITDA multiple in the mid-to-high double digits, one of the sources said.
Read the full article: Isto Biologics Taps DC Advisory to Explore Sale //
Source: https://ionanalytics.com/insights/mergermarket/isto-biologics-taps-dc-advisory-to-explore-sale/